Should you buy Biohaven stock?

There's ample reason for investors to be interested in Biohaven. Pfizer acquired the "old" Biohaven's successful migraine drug Nurtec ODT, and zavegepant, which awaits U. S. regulatory approval for treating migraine. However, the "new" Biohaven retained a pipeline focused on neuroscience and rare diseases.

How much is Biohaven Ltd (bhvn) worth?

At the end of the latest market close, Biohaven Ltd. (BHVN) was valued at $14.41. In that particular session, Stock kicked-off at the price of $14.97 while reaching the peak value of $15.11 and lowest value recorded on the day was $13.12.

Who owns Biohaven Ltd stock?

Upon looking at major shareholders, it appears that insiders hold 14. 67% of Biohaven Ltd. shares, and 45. 60% of them are in the hands of institutional investors. The stock currently has a share float of 53. 44%. Biohaven Ltd. stock is held by 155 institutions, with Armistice Capital, LLC being the largest institutional investor.